NSF Approves Flex Pharma’s Proprietary Formulation Under NSF’s Certified For Sport Program

BOSTON--(BUSINESS WIRE)--Click to Tweet this News

“This is an important step forward as our talented team works to develop and bring to market a proprietary formulation for consumers based upon Dr. MacKinnon’s breakthrough scientific insight.”

Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that its proprietary formulation has earned certification from NSF International's Certified for Sport® program. Flex Pharma’s Consumer division is developing consumer products based on the scientific insights of Nobel Prize winning neuroscientist, Dr. Rod MacKinnon and Harvard Medical School Professor of Neurobiology, Bruce Bean, Ph.D., both Scientific Co-Founders of Flex Pharma.

NSF's Certified for Sport® program certifies ingredients and tests products to ensure they do not contain contaminants or banned or prohibited substances. The MLB, MLB Player's Association, NFL, NFL Player's Association, PGA, LPGA and the CCES (Canadian Centre for Ethics in Sport) have all chosen NSF's Certified for Sport® program.

“We are very pleased to receive NSF certification, a critical milestone in the development of our company,” said John Sculley, former CEO of Pepsi and Apple and Flex Pharma Board member and investor. “This is an important step forward as our talented team works to develop and bring to market a proprietary formulation for consumers based upon Dr. MacKinnon’s breakthrough scientific insight.”

"What we’re developing will be a real game changer - literally and figuratively - for high achievers that want to be unstoppable and are interested in products that optimize athletic performance and provide peace of mind,” said Marina Hahn, President of Flex Pharma’s Consumer division, whose background includes leading roles at Pepsi, Quirky and SVEDKA Vodka. “Our proprietary formulation has the potential to inform a range of products in the healthy active lifestyle category, so having NSF’s validation is solid progress towards this goal.”

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

About NSF International

NSF International certifies products and writes standards for food, water, dietary supplements and consumer goods to minimize adverse health effects (www.nsf.org). Founded in 1944, NSF is committed to protecting human health and safety worldwide and operates in more than 120 countries. NSF is a World Health Organization Collaborating Centre for Food and Water Safety and Indoor Environment.

NSF's Dietary Supplement Certification program certifies that what is on the label is in the bottle and that the product does not contain contaminants.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our plans to develop and commercialize our consumer products, attributes of our consumer products and the market acceptance of our consumer products. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, our ability to develop and commercialize our consumer products; demand for our consumer products; anticipated positioning and attributes of our consumer products; other matters that could affect the commercial potential of our consumer products; and other factors discussed in greater detail under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.